Drug Profile
Research programme: anticancer therapeutics - NexusPharma
Alternative Names: p53-MDM2 Inhibitors - NexusPharmaLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator NexusPharma
- Class Small molecules
- Mechanism of Action Proto-oncogene protein c mdm2 inhibitors; Tumour suppressor protein p53 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Germany
- 11 Oct 2010 Preclinical development is ongoing in Germany
- 09 Sep 2005 Preclinical trials in Cancer in Germany (unspecified route)